Drug updated on 3/19/2024
| Dosage Form | Tablet (oral; 200 mg, 550 mg) |
| Drug Class | Rifamycin antibacterial |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for treatment of travelers’ diarrhea (TD) caused by noninvasive strains of Escherichia coli in adult and pediatric patients 12 years of age and older.
- Indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.
- Indicated for treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Latest News
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Efficacy of rifaximin in patients with abdominal bloating or distension a systematic review and meta-analysis. | 2023 | Journal of Clinical Gastroenterology |
| Role of rifaximin in the management of alcohol-associated hepatitis: a systematic review and meta-analysis. | 2023 | Journal of Gastroenterology and Hepatology |
| Xifaxan (rifaximin) Prescribing Information. | 2022 | Salix Pharmaceuticals, Bridgewater, NJ |
| The American Society of Colon and Rectal Surgeons clinical practice guidelines for the treatment of left-sided colonic diverticulitis. | 2020 | Diseases of the Colon and Rectum |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| ACG clinical guideline: management of irritable bowel syndrome | 2021 | The American Journal of Gastroenterology |